PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

Leukemia

Volumn 22, Issue 9, 2008, Pages 1698-1706

  Park, S ^a,b,c   Chapuis, N ^a,b   Bardet, V ^a,b,c   Tamburini, J ^a,b,c   Gallay, N ^d   Willems, L ^a,b   Knight, Z A ^e   Shokat, K M ^e   Azar, N ^f   Viguie F ^g   Ifrah, N ^h   Dreyfus, F ^a,b,c   Mayeux, P ^a,b   Lacombe, C ^a,b,c   Bouscary, D ^a,b,c  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c Hôpital Cochin ^*  (France)

^d CHU PURPAN   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; CD34 ANTIGEN; ETOPOSIDE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; FURANS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDINES; PYRIMIDINES; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 51649088622     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.144     Document Type: Article

References (26)

1. Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol 2005; 82: 389-396.
2. Dick JE. Stem cells: Self-renewal writ in blood. Nature 2003; 423: 231-233.
3. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA 2003; 100 (Suppl 1): 11842-11849.
4. Bardet V, Tamburini J, Ifrah N, Dreyfus F, Mayeux P, Bouscary D et al Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica 2006; 91: 757-764.
5. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires P13 kinase activation. Blood 2003; 102: 972-980.
6. Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broet P et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 2007; 110: 1025-1028.
7. Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable. Leukemia 2003; 17: 995-997.
8. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005; 106: 1063-1066.
9. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B et al. A selective inhibitor of the p110delta isoform of Pl 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006; 25: 6648-6659.
10. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
11. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005; 106: 4261-4268.
12. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527-2534.
13. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L et al mTORC1 inhibition activates PI3K/Akt by up-regulating IGF-1R signaling in acute myeloid leukemia: Rational for therapeutic inhibition of both pathways. Blood 2008; 111: 379-382.
14. Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 2004; 12: 4749-4759.
15. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125: 733-747.
16. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of-epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007; 67: 7960-7965.
17. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341-349.
18. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: Evidence for Fas-dependent apoptosis. Blood 2002; 99: 1594-1601.
19. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
20. Recher C, Dos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005; 4: 1540-1549.
21. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006; 20: 911-928.
22. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007; 21: 886-896.
23. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM et al Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22: 147-160.
24. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C. A critical role for Lyn in acute myeloid leukemia. Blood 2008; 111: 2269-2279.
25. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007; 67: 5840-5850.
26. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Gronning LM et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 2007; 404: 449-458.